Skip to main content

Advertisement

SpringerLink
Log in

Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Objective Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are involved in the tumorigenesis and regulation of cell metabolism via Akt signaling. F-18 fluorodeoxyglucose-positron emission tomography ([18F]FDG PET), a functional imaging modality, can be used to measure tumor cell metabolism. Thus, in this study, we hypothesize that there exist correlations between EGFR mutation status and [18F]FDG uptake of advanced lung adenocarcinoma. Methods From May 2004 to April 2008, patients with stage IIIB or IV lung adenocarcinoma who underwent [18F]FDG PET and EGFR mutation analysis before receiving any treatment were eligible to participate in this study. The association of EGFR mutation status with patient characteristics and the SUVMAX from the [18F]FDG PET was evaluated. Multivariate logistic regression analysis was used to analyze predictors of EGFR mutations. Results Seventy-seven lung adenocarcinoma patients were included in this study. EGFR mutations were identified in 49 (64%) of the patients. The [18F]FDG uptake was significantly higher in EGFR-mutant (mean SUVMAX = 10.5 ± 4.7) than wild-type (8.0 ± 3.3) lung adenocarcinoma patients (P = 0.008). The median SUVMAX was 9.5, and patients with an SUVMAX ≥ 9.5 were more likely to harbor EGFR mutations (P = 0.009). In the multivariate analysis, an SUVMAX ≥ 9.5 remained a statistically significant predictor of EGFR mutations (P = 0.005). Conclusions Among Asian patients with advanced lung adenocarcinoma, those with higher SUVMAX on the [18F]FDG PET are more likely to carry EGFR mutations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Health Statistics in Taiwan, 2007. Department of Health, Executive Yuan, Taiwan, ROC.

  2. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell. 2002;1:49–52. doi:10.1016/S1535-6108(02)00027-2.

    Article  CAS  PubMed  Google Scholar 

  3. Chen KY, Chang CH, Yu CJ, Kuo SH, Yang PC. Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma. Cancer. 2005;103:2566–74. doi:10.1002/cncr.21087.

    Article  PubMed  Google Scholar 

  4. Jorissen RN, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284:31–53. doi:10.1016/S0014-4827(02)00098-8.

    Article  CAS  PubMed  Google Scholar 

  5. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–37. doi:10.1038/35052073.

    Article  CAS  PubMed  Google Scholar 

  6. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163–7. doi:10.1126/science.1101637.

    Article  CAS  PubMed  Google Scholar 

  7. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905–27. doi:10.1101/gad.13.22.2905.

    Article  CAS  PubMed  Google Scholar 

  8. Kohn AD, Summers SA, Birnbaum MJ, Roth RA. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem. 1996;271:31372–8. doi:10.1074/jbc.271.49.31372.

    Article  CAS  PubMed  Google Scholar 

  9. Hajduch E, Litherland GJ, Hundal HS. Protein kinase B (PKB/Akt)—a key regulator of glucose transport? FEBS Lett. 2001;492:199–203. doi:10.1016/S0014-5793(01)02242-6.

    Article  CAS  PubMed  Google Scholar 

  10. Mac Manus MP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003;21:1285–92. doi:10.1200/JCO.2003.07.054.

    Article  PubMed  Google Scholar 

  11. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer. 2002;35:179–87. doi:10.1016/S0169-5002(01)00332-4.

    Article  PubMed  Google Scholar 

  12. Vanuytsel LJ, et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 2000;55:317–24. doi:10.1016/S0167-8140(00)00138-9.

    Article  CAS  PubMed  Google Scholar 

  13. Vesselle H, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837–44.

    CAS  PubMed  Google Scholar 

  14. Downey RJ, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255–60. doi:10.1200/JCO.2004.11.109.

    Article  PubMed  Google Scholar 

  15. Downey RJ, Akhurst T, Gonen M, Park B, Rusch V. Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007;133:1419–27. doi:10.1016/j.jtcvs.2007.01.041.

    Article  PubMed  Google Scholar 

  16. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005;130:151–9. doi:10.1016/j.jtcvs.2004.11.007.

    Article  PubMed  Google Scholar 

  17. Kurata T, Oguri T, Isobe T, Ishioka S, Yamakido M. Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases. Jpn J Cancer Res. 1999;90:1238–43.

    CAS  PubMed  Google Scholar 

  18. Higashi K, et al. Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med. 2000;27:1778–85. doi:10.1007/s002590000367.

    Article  CAS  PubMed  Google Scholar 

  19. Mamede M, et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 2005;7:369–79. doi:10.1593/neo.04577.

    Article  CAS  PubMed  Google Scholar 

  20. Shih JY, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer. 2006;118:963–9. doi:10.1002/ijc.21458.

    Article  CAS  PubMed  Google Scholar 

  21. Kelly K, Huang C. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. J Thorac Oncol. 2008;3:664–73. doi:10.1097/JTO.0b013e3181758141.

    Article  PubMed  Google Scholar 

  22. Perez-Soler R, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22:3238–47. doi:10.1200/JCO.2004.11.057.

    Article  CAS  PubMed  Google Scholar 

  23. Kris MG, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149–58. doi:10.1001/jama.290.16.2149.

    Article  CAS  PubMed  Google Scholar 

  24. Massarelli E, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer. 2003;39:55–61. doi:10.1016/S0169-5002(02)00308-2.

    Article  CAS  PubMed  Google Scholar 

  25. Inoue A, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 2006;24:3340–6. doi:10.1200/JCO.2005.05.4692.

    Article  CAS  PubMed  Google Scholar 

  26. Asahina H, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer. 2006;95:998–1004. doi:10.1038/sj.bjc.6603393.

    Article  CAS  PubMed  Google Scholar 

  27. Pao W, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306–11. doi:10.1073/pnas.0405220101.

    Article  CAS  PubMed  Google Scholar 

  28. Paez JG, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500. doi:10.1126/science.1099314.

    Article  CAS  PubMed  Google Scholar 

  29. Lynch TJ, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39. doi:10.1056/NEJMoa040938.

    Article  CAS  PubMed  Google Scholar 

  30. Yang CH, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol. 2008;26:2745–53. doi:10.1200/JCO.2007.15.6695.

    Article  CAS  PubMed  Google Scholar 

  31. Marchetti A, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23:857–65. doi:10.1200/JCO.2005.08.043.

    Article  CAS  PubMed  Google Scholar 

  32. Cappuzzo F, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643–55.

    Article  CAS  PubMed  Google Scholar 

  33. Fischer BM, Mortensen J, Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol. 2001;2:659–66. doi:10.1016/S1470-2045(01)00555-1.

    Article  CAS  PubMed  Google Scholar 

  34. Sasaki R, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23:1136–43. doi:10.1200/JCO.2005.06.129.

    Article  CAS  PubMed  Google Scholar 

  35. Weber WA, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651–7. doi:10.1200/JCO.2003.12.004.

    Article  CAS  PubMed  Google Scholar 

  36. Su H, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006;12:5659–67. doi:10.1158/1078-0432.CCR-06-0368.

    Article  CAS  PubMed  Google Scholar 

  37. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355–65. doi:10.1038/35077225.

    Article  CAS  PubMed  Google Scholar 

  38. Cappuzzo F, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2004;96:1133–41.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This study was supported by the Department of Medical Research of the National Taiwan University Hospital and by grant (NSC-95-2314-B-002-110-MY3 for J.-Y. Shih) from the National Science Council, Taiwan.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Br., Yun-Lin County, Taiwan

    Chun-Ta Huang

  2. Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan

    Rouh-Fang Yen & Mei-Fang Cheng

  3. Department of Internal Medicine, Division of Pulmonary Medicine, National Taiwan University Hospital, # 7, Chung-Shan South Rd, Taipei, 100, Taiwan

    Ya-Chieh Hsu, Jin-Yuan Shih & Pan-Chyr Yang

  4. Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

    Pin-Fei Wei

  5. School of Medicine, College of Medicine, Fu-Jen Catholic University, Taipei, Taiwan

    Yi-Ju Tsai

  6. Department of Molecular Biotechnology, Da-Yeh University, Chang-Hua, Taiwan

    Meng-Feng Tsai

  7. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan

    Chih-Hsin Yang

Authors
  1. Chun-Ta Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rouh-Fang Yen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mei-Fang Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ya-Chieh Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pin-Fei Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yi-Ju Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Meng-Feng Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jin-Yuan Shih
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chih-Hsin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pan-Chyr Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jin-Yuan Shih.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, CT., Yen, RF., Cheng, MF. et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol 27, 9–15 (2010). https://doi.org/10.1007/s12032-008-9160-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-008-9160-1

Keywords

Search

Navigation